Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

Video

In Partnership With:

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer (CRPC).

Related Videos
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Related Content
Spencer Heaton, MD, MBA, of Lynx Dx

New Prostate Cancer Urine Test Produces Greater Diagnostic Accuracy vs Existing Tests in High-Grade Prostate Cancer

April 23rd 2024
Article
Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023
Podcast
Ebrahim Delpassand, MD, of Excel Diagnostics and Nuclear Oncology Center

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

April 10th 2024
Article
Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023
Podcast
Ruben Olivares, MD

Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer

April 5th 2024
Article
Phillip J. Koo, MD, chief of Diagnostic Imaging at Banner MD Anderson Cancer Center in Phoenix, Arizona

Koo Looks to the Future With PSMA PET Imaging in Prostate Cancer

April 4th 2024
Article